Frequently Asked Questions

Answers to Frequently Asked Questions about the ExCITE translational research grant program at the University of Louisville.
Why is EXCITE different from other grant programs?

It is important to note that the ExCITE program is not a traditional grant program; it is product-focused and requires business-case project management. Applicants who are invited to submit a full application will work with a mentor to develop a product development plan and timeline with specified milestones.

What benchmarks will I have to meet in the program?

Receipt of funding for selected projects will be milestone-driven and ExCITE staff will monitor project progress. There will be a continuation evaluation (go/no-go decision) about every six months and non-progressing projects may be terminated and replaced with new projects.

Who is eligible for the ExCITE program?

This RFA is open to all UofL faculty, staff, trainees, and students. Non-faculty applicants must identify a UofL faculty member who is willing to sponsor their application. Applications must focus on developing products that have the potential to improve patient care or enhance human health.

All types of products (e.g. therapeutic, preventative, device, test, software) are eligible. Previously funded projects from Cycles 1 through 5 are eligible for competitive renewal. Having multiple Principal Investigators (up to three) is optional but permitted.

Does my product have to treat one specific disease?

There is no disease-specific requirement, but some funds are restricted.

What’s the policy on intellectual property?

Applications should involve ideas that originate from UofL (making them potentially eligible for patent protection or some other mechanism that will return income to the program) or UofL-derived technologies with pending/issued patents or copyright. Technologies that are already licensed to a company are not eligible.

What’s the budget?

Requests for $25,000 to $50,000 total per project, over a period of up to 8 months, will be considered.

Are there budget limitations?

Of the $1 million per year available, at least $150,000 must support lung cancer-related projects and at least $200,000 must support projects focusing on plant-produced pharmaceuticals.